← Back to Home

Novartis Bets $1.5 Billion on Myricx as ADC Boom Shifts Toward More Sophisticated Cytotoxic Payloads

The race in antibody-drug conjugates is moving from “getting the drug to the tumor” to “what is being delivered.” Novartis’ acquisition of the still early-stage UK startup Myricx shows that large pharmaceutical companies are willing to place early bets on next-generation cancer payload platforms.

By SURL BioNews

Cancer drug development has become newly enamored with antibody-drug conjugates in recent years, and the reason is not hard to understand: they work like a precision delivery system, using antibodies to seek out tumor cells and then bringing potent small-molecule drugs near the target. But the value of this technology lies not only in whether the antibody can find the tumor, but also in whether the “warhead” it carries can create enough therapeutic effect while avoiding intolerable toxicity. Novartis’ acquisition of the UK startup Myricx Bio is a signal that this competition is entering a more refined stage.

According to reports by The Guardian, the Financial Times, and others, Novartis has agreed to acquire London-based Myricx Bio for up to $1.5 billion, including an upfront payment of $1.1 billion and up to $400 million in milestone payments. The deal gives Novartis access to Myricx’s N-myristoyltransferase (NMT) inhibitor payload platform and strengthens its antibody-drug conjugate pipeline.

Myricx was founded in 2019. According to the Financial Times and The Times, its technology originated from research at Imperial College London and the Francis Crick Institute, and its founders include Ed Tate, Roberto Solari, and Andrew Bell. The company previously completed a £90 million Series A financing, with investors including Novo Holdings, Abingworth, British Business Bank, Cancer Research Horizons, and Eli Lilly, among others. For a company still hovering around the early clinical stage, that valuation itself illustrates the market’s appetite for new ADC payloads.

ADCs are not a new concept, but the focus of the latest wave of competition is no longer simply attaching traditional cytotoxic drugs to antibodies. The NMT inhibitors emphasized by Myricx target enzymes related to intracellular protein lipid modification; if they can be selectively delivered into tumor cells in ADC form, they could in theory open a therapeutic window different from existing payloads. However, there is still a long distance between biological rationale and clinical proof for mechanisms of this kind.

The Financial Times noted that Myricx’s two lead assets are early-stage ADCs aimed at delivering differentiated cancer-cell-killing payloads into tumor cells. This also means that what Novartis is buying is not a mature product validated by large-scale clinical data, but a platform, a set of drug candidates, and a judgment about future mechanisms. Barclays analysts also reportedly said that, given the lack of clinical data, the price appears high, but the transaction fits Novartis’ oncology strategy.

**Background Context**

Large pharmaceutical companies have continued to increase their investment in ADCs in recent years, not only because some products have already demonstrated commercial and clinical value in breast cancer, lung cancer, and blood cancers, but also because these drugs tie antibody engineering, linker chemistry, payload design, and manufacturing capabilities into the same competitive chain. As capacity and quality control have become bottlenecks, the ability to obtain a truly differentiated payload platform has become another entry point for early positioning.

This acquisition therefore should not be interpreted only as a high-priced exit for a single UK startup. It is more like Novartis’ bet on the next round of technological differentiation in ADCs: looking beyond currently popular targets for more distinct cancer-cell-killing mechanisms. But for patients and clinicians, the truly important questions remain unanswered, including whether efficacy is superior to existing therapies, whether toxicity is controllable, which tumors are most likely to benefit, and whether an early-stage platform can get through the harshest screening process in human trials.

References

  1. The Guardian
  2. Financial Times
  3. The Times